Influence of chronic renal failure on stereoselective metoprolol metabolism in hypertensive patients

Journal of Clinical Pharmacology

Volumn 45, Issue 12, 2005, Pages 1422-1433

  Cerqueira, Paula Macedo ^a   Coelho, Eduardo Barbosa ^a   Geleilete, Tufik José Magalhães ^a   Goldman, Gustavo Henrique ^a   Lanchote, Vera Lucia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chronic renal failure; Metabolism; Metoprolol; Pharmacokinetics; Stereoselectivity

Indexed keywords

4ALPHA HYDROXYMETOPROLOL; ALPHA HYDROXYMETOPROLOL; BEZAFIBRATE; CLOBAZAM; CYTOCHROME P450 2D6; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DIAZEPAM; DRUG METABOLITE; METOPROLOL TARTRATE; SIMVASTATIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; ENANTIOMER; ENZYME INDUCTION; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; MALE; MULTIPLE DRUG DOSE; STEREOCHEMISTRY; URINARY EXCRETION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTIHYPERTENSIVE AGENTS; CYTOCHROME P-450 CYP2D6; DEBRISOQUIN; FEMALE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; METOPROLOL; MIDDLE AGED; MUTATION; STEREOISOMERISM;

EID: 27844474695     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005281816     Document Type: Article

References (39)

1. Bernareggi A. Farmacocinetica di principi attivi chirali. Boll Chim Farm. 1995;134:63-68.
2. Tucker GT: Chiral switches. Lancet. 2000;355:1085-1087.
3. Dayer P, Leemann T, Marmy A, Rosenthaler J: Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol. Eur J Clin Pharmacol. 1985;28:149-153.
4. Wallf T, Webb JG, Bagwell EE, Walle UK, Daniel HB, Gaffney TE. Stereoselective delivery and actions of beta-receptor antagonists. Biochem Pharmacol. 1988;37:115-124.
5. Johnson JA, Burlew BS. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab Dispos. 1996;24:350-355.
6. Jonkers RE, Koopmans RP, Portier EJG, van Boxtel CJ. Debrisoquine phenotype and the pharmacokinetics and Beta-2 receptor pharmacodynamics of metoprolol and its enantiomers. J Pharmacol Exp Ther. 1991;256:959-966.
7. Leemann TD, Devi KP, Dayer P. Similar effect of oxidation deficiency (debrisoquine polymorphism) and quinidine on the apparent volume of distribution of (±)-metoprolol. Eur J Clin Pharmacol. 1993;45:65-71.
8. Cerqueira PM, Cesarino EJ, Mateus FH, Mere Y Jr, Santos SRCJ, Lanchote VL. Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. Chirality. 1999;11:591-597.
9. Collett A, Tanianis-Hughes J, Warhurst G. Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interaction? Biochem Pharmacol. 2004;68:783-790.
10. 1-receptor antagonist metoprolol in man. J Pharmacokinet Biopharm. 1974;2:347-364.
11. 3) in man, the dog and the rat. Acta Pharmacol Toxicol. 1975;36(Suppl 5):125-135.
12. Hoffmann K-J, Regardh CG, Aurell M, Ervik M, Jordö L. The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites. Clin Pharmacol. 1980;5:181-191.
13. Madani S, Paine MF, Lewis L, Thummel KE, Shen DD. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharma Res. 1999;16:1199-1205.
14. Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther. 1988;247:242-247.
15. Mautz DS, Nelson WL, Shen DD. Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsomes containing cDNA-expressed human P4502D6. Drug Metab Dispos. 1995;23:513-517.
16. Murthy SS, Shetty HU, Nelson WL, Jackson PR, Lennard MS. Enantioselective and diastereoselective aspects of the oxidative metabolism of metoprolol. Biochem Pharmacol. 1990;40:1637-1644.
17. Zineth I, Beitelshees AL, Gaedigk A, et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther. 2004;76:536-544.
18. Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, Woods HF. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquine metabolizers. Clin Pharmacol Ther. 1983;34:732-737.
19. Lennard MS, Tucker GT, Woods HE, Silas JH, Iyun AO. Stereoselective metabolism of metoprolol in Caucasians and Nigerians: relationship to debrisoquine oxidation phenotype. Br J Clin Pharmacol. 1989;27:613-616.
20. Dowling TC, Briglia AE, Fink JC, et al. Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther. 2003;73:427-434.
21. Lanchote VL, Ping WC, Santos SRCJ. Influence of renal failure on cytochrome P450 activity in hypertensive patients using a "cocktail" of antipyrine and nifedipine. Eur J Clin Pharmacol. 1996;50:83-89.
22. Leblond FA, Petrucci M, Dubé P, Bernier G, Bonnardeaux A, Pichette V. Downregulation of intestinal cytochrome P450 in chronic renal failure. J Am Soc Nephrol. 2002;13:1579-1585.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976:16:31-41.
24. National Kidney Foundation K/DOQI. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S246.
25. Tucker GT, Silas JH, Iyun AO, Lennard MS, Smith AJ. Polymorphic hydroxylation of debrisoquine. Lancet. 1977;2:718.
26. Heim MH, Meyer UA. Genetic polymorphism of debrisoquine oxidation: restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6. Meth Enzimol. 1991;206:173-183.
27. Cerqueira PM, Mateus FH, Cesarino EJ, Lanchote VL. Enantioselectivity of debrisoquine 4-hydroxylation in Brazilian Caucasian hypertensive patients phenotypedas extensive metabolizers. J Chromatogr B Biomed Sci Appl. 2000;749:153-161.
28. Cerqueira PM, Cesarino EJ, Bertucci C, Bonato PS, Lanchote VL. Stereoselective metabolism of metoprolol: enantioselectivity of α-hydroxymetoprolol in plasma and urine. Chirality. 2003;15:542-549.
29. Lanchote VL, Bonato PS, Cerqueira PM, Pereira VA, Cesarino EJ. Enantioselective analysis of metoprolol in plasma using high-performance liquid chromatographic direct and indirect separations: applications in pharmacokinetics. J Chromatogr B. 2000;738:27-37.
30. Cerqueira PM, Boralli VB, Coelho EB, et al. Enantioselective determination of metoprolol acidic metabolite in plasma and urine using liquid chromatography chiral columns: applications to pharmacokinetics. J Chromatogr B. 2003;783:433-441.
31. Shargel L, Yu ABC. Applied Biopharmaceutics and Pharmacokinetics. London: Prentice Hall, 1993.
32. Sohn DR, Kusaka M, Shin SG, Jang I-J, Chiba K, Ishizaki T. Utility of a one-point (3-hour postdose) plasma metabolic ratio as a phenotyping test using metoprolol in two East Asian populations. Ther Drug Monit. 1992;14:184-189.
33. Tucker GT. Advances in understanding drug metabolism and its contribution to variability in patients response. Ther Drug Monit. 2000;22:110-113.
34. Kaisary A, Smith P, Jaczq E, et al. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res. 1987;47:5488-5493.
35. Rostami-Hodjegan A, Funck-Brentano C, Kroemer HK, Tucker GT. In vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity. Br J Clin Pharmacol. 1999;47:575P-602P.
36. Basci NE, Bozkurt A, Isimer A, Kayaalp SO. Correlation between the metabolic ratios of debrisoquine and metoprolol in Turkish subjects. Pharmacol Toxicol. 1994;75:62-64.
37. McGourty JC, Silas JH. Metoprolol metabolism and debrisoquine oxidation polymorphism: population and family studies. Br J Clin Pharmacol. 1985;20:555-566.
38. Mistry B, Leslie J, Eddington NE. Influence of input rate on the stereospecific and nonstereospecific first pass metabolism and pharmacokinetics of metoprolol extended release formulations. Chirality. 2002;14:297-304.
39. Lloyd P, John VA, Signy M, Smith SE. The effect of impaired renal function on the pharmacokinetics of metoprolol after single administration of a 14/190 metoprolol OROS system. Am Heart J. 1990;120:478-482.